Skip to main content
Premium Trial:

Request an Annual Quote

Nabsys Nabs $7M in Venture Funds

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – DNA sequencing developer Nabsys said today that it has reeled in $7 million in Series B venture financing in an equity round led by Stata Venture Partners.

The Providence, RI-based firm said it plans to use the financing to speed up development and commercialization of its core platform, which uses semiconductor technology in a solid-state DNA sequencing tool.

In 2009, Nabsys completed a $4 million equity round.

Nabsys President and CEO Barrett Bready said that the "sequencing technology utilizes established semiconductor fabrication techniques, allowing for the rapid development of sequencing platforms at a scale and speed never before possible."

Ray Stata, founder of Stata Venture Partners, said that Nabsys "represents the merger of two industries which, until now, have been quite disparate: semiconductors and genomics." He added that he expects the technology to be a "significant breakthrough in making DNA sequencing clinically relevant and widely available."

In connection with the investment, Stata was named to Nabsys' board of directors.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.